4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To study the long-term efficacy and safety of 4-aminopyridine in patients with multiple sclerosis. DESIGN: Case series, follow-up varying from 6 to 32 months. SETTING: University referral center. PATIENTS: Thirty-one patients with definite MS, 23 of them being exposed to long-term administration (6 to 32 months) of 4-aminopyridine, since they showed a favorable initial response to the drug. INTERVENTIONS: Long-term oral treatment with 4-aminopyridine in daily doses of up to 0.5 mg/kg of body weight. MAIN OUTCOME MEASURES: Neurologic functions and symptoms as reported by the patients; side effects. RESULTS: Twenty of 23 patients who showed a favorable initial response benefited from long-term administration. Ambulation and fatigue (each in 13 patients) and visual function (in five patients) were most frequently reported to be improved. Three major side effects did occur during a follow-up of 406 patient months: a generalized epileptic seizure in two patients and hepatitis in one. CONCLUSIONS: Although a substantial proportion of patients with multiple sclerosis seem to benefit from long-term administration of 4-aminopyridine, additional studies are needed to clarify the exact value of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Brañas, Jordan, Fry-Smith, Burls, & Hyde (2000) · Health Technology Assessment · doi:10.3310/hta4270 · Cited by 330
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000158272.27070.6a · Cited by 318
Anti-spasticity agents for multiple sclerosis
Shakespeare, D., Boggild, M., & Young, C. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001332 · Cited by 271
Judge, S. I. V., & Bever, C. T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.006 · Cited by 268
Hadjimichael, O., Vollmer, T., & Oleen-Burkey, M. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-100 · Cited by 240
“While no drugs are currently FDA approved for the symptomatic treatment of MS fatigue, several drugs, such as amantadine, modafinil, pemoline, and 4-aminopyridine, have been shown to provide benefit [15,35,50,51].”
Metadata
- Authors
- Polman, C. H.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1994-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 292
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1996607415
- Cited by
- 122
- References
- 0
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety. https://app.cochat.ai/papers/10.1001/archneur.1994.00540150090022
- The paper
- Polman, C. H. (1994). 4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety. Archives of Neurology. https://doi.org/10.1001/archneur.1994.00540150090022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.